20 Years Experience of Tnf-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: Tnf Dose Matters
Annals of surgical oncology(2011)
Abstract
Approximately 5–8% of melanoma patients will develop in-transit metastases (IT-mets). Tumor necrosis factor-α (TNF) and melphalan-based isolated limb perfusion (TM-ILP) is an attractive treatment modality in melanoma patients with multiple IT-mets. This study reports on a 20 years experience and outlines the evolution and major changes since the introduction of TNF in ILP.
MoreTranslated text
Key words
Overall Survival,Soft Tissue Sarcoma,Melanoma Patient,Ipilimumab,Complete Response Rate
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined